[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100485673":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":37,"centralContacts":44,"locations":50,"responsibleParty":65,"collaborators":69,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":32,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":53,"whyStopped":32,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Indiana University","OTHER",[8,14,18,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Hemorrhagic Myocardial Infarction - Deferiprone","ACTIVE_COMPARATOR","Enrolled patients with CMR confirmed presence of intramyocardial hemorrhage",[13],"Drug: Deferiprone Tablets",{"label":15,"type":10,"description":16,"interventionNames":17},"Non-hemorrhagic Myocardial Infarction - Deferiprone","Enrolled patients with CMR confirmed absence of intramyocardial hemorrhage",[13],{"label":19,"type":20,"description":11,"interventionNames":21},"Hemorrhagic Myocardial Infarction - Placebo","PLACEBO_COMPARATOR",[22],"Drug: Placebo",{"label":24,"type":20,"description":16,"interventionNames":25},"Non-hemorrhagic Myocardial Infarction - Placebo",[22],[27,33],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Deferiprone Tablets","Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.",[9,15],null,{"type":28,"name":34,"description":35,"armGroupLabels":36,"otherNames":32},"Placebo","Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.",[19,24],[38,42],{"name":39,"affiliation":40,"role":41},"Keyur P Vora, MD FACP FACC","Medical Imaging Research Institute, Indiana University School of Medicine","PRINCIPAL_INVESTIGATOR",{"name":43,"affiliation":40,"role":41},"Rohan Dharmakumar, PhD",[45],{"name":46,"role":47,"phone":48,"phoneExt":32,"email":49},"Clinical Research Coordinator","CONTACT","(317) 274-0985","csaha@iu.edu",[51],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":32},"IU Methodist Hospital (IUHealth)","RECRUITING","Indianapolis","Indiana","46202","United States","US",{"type":60,"coordinates":61},"Point",[62,63],-86.15804,39.76838,{"lat":63,"lon":62},{"type":66,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"SPONSOR_INVESTIGATOR","Rohan Dharmakumar","Executive Director, Medical Imaging Research Institute",[70],{"name":71,"class":6},"Minneapolis Heart Institute","100485673","phase-2-cardiac-mri-guided-deferiprone-therapy-for-acute-myocardial-infarction-patients-100485673",false,"NCT05604131","Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients","MIRON-DFP","Inclusion Criteria\n\n1. Age 18-79 years\n2. Index Anterior wall STEMI\n3. Emergency coronary angiogram with primary PCI\n\nExclusion Criteria\n\n1. Prior history of MI \u002F PCI \u002F coronary artery bypass graft (CABG) within previous 1 year\n2. Patients with previous history of left ventricular ejection fraction (LVEF) \\\u003C 40%\n3. Use of investigational drugs or devices 30 days prior to randomization\n4. Known allergy or contra-indication to gadolinium\u002Fcontrast agents\n5. eGFR \\\u003C 30 ml\u002Fkg\u002Fmin\n6. Any contraindication against cardiac MRI (such as metal implants)\n7. Women who are pregnant or breastfeeding. Women of reproductive potential must have a negative pregnancy test prior to randomization\n8. Body weight \\> 140 kg (or 309 lbs.)\n9. Absolute neutrophil count - ANC \\\u003C 1.5 k\u002Fcumm\n10. History of Chronic Liver Disease\n11. Elevated hepatic enzymes (BOTH ALT and AST) \\> 2 times of upper normal limit\n12. Patients with iron storage disease (hemochromatosis, thalassemia) or who are already treated with iron chelators\n13. Any clinically significant abnormality identified prior to randomization that in the judgment of the Sponsor-Investigator or Delegate would preclude safe completion of the study or confound the anticipated benefit of deferiprone.\n14. Life expectancy of less than 1 year due to non-cardiac pathology","ALL","18 Years","79 Years",{"count":83,"type":84},89,"ESTIMATED","INTERVENTIONAL",[87],"PHASE2","The objective of this randomized, controlled pilot study is to determine the efficacy of Deferiprone to reduce the amount of free iron inside the hemorrhagic zone of myocardial infarction among hemorrhagic myocardial infarction patients.",[90],"Acute Myocardial Infarction Type 1",[92,93,94],"Acute Myocardial Infarction","Intramyocardial Hemorrhage","Deferiprone","2026-04-02",{"date":97,"type":98},"2026-04-08","ACTUAL",{"date":100,"type":98},"2022-11-08",{"date":102,"type":84},"2029-08-31",{"name":67,"class":6},1]